Visual defects reported with Levitra

Patients taking Levitra (vardenafil) for the treatment of erectile dysfunction should be warned to stop taking the product and to consult a physician immediately if they develop any sudden visual defects.

The warning has been issued following reports of visual defects and cases of non-arteritic ischaemic optic neuropathy in patients taking Levitra and other PDE5 inhibitors.

Further information: Bayer Plc, Strawberry Hill, Newbury, Berks RG14 1JA. Tel: (01635) 563000.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more